Allogene Therapeutics (ALLO) Accumulated Depreciation & Amortization (2019 - 2025)
Historic Accumulated Depreciation & Amortization for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $9.3 million.
- Allogene Therapeutics' Accumulated Depreciation & Amortization fell 1060.93% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 1060.93%. This contributed to the annual value of $13.6 million for FY2024, which is 395.07% down from last year.
- Latest data reveals that Allogene Therapeutics reported Accumulated Depreciation & Amortization of $9.3 million as of Q3 2025, which was down 1060.93% from $6.2 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Accumulated Depreciation & Amortization registered a high of $40.4 million during Q1 2023, and its lowest value of $3.1 million during Q1 2025.
- For the 5-year period, Allogene Therapeutics' Accumulated Depreciation & Amortization averaged around $15.5 million, with its median value being $13.6 million (2024).
- Per our database at Business Quant, Allogene Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 10128.99% in 2021 and then crashed by 9119.88% in 2024.
- Quarter analysis of 5 years shows Allogene Therapeutics' Accumulated Depreciation & Amortization stood at $10.5 million in 2021, then soared by 36.19% to $14.3 million in 2022, then decreased by 0.7% to $14.2 million in 2023, then fell by 3.95% to $13.6 million in 2024, then plummeted by 31.8% to $9.3 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $9.3 million for Q3 2025, versus $6.2 million for Q2 2025 and $3.1 million for Q1 2025.